scholarly article | Q13442814 |
P356 | DOI | 10.1097/JTO.0B013E3181C5E334 |
P698 | PubMed publication ID | 20009775 |
P2093 | author name string | Lisa A Rybicki | |
Jerrold P Saxton | |||
Thomas W Rice | |||
Gregory M M Videtic | |||
David P Mason | |||
Sudish C Murthy | |||
David J Adelstein | |||
Cristina P Rodriguez | |||
Denise I Ives | |||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | chemotherapy | Q974135 |
P1104 | number of pages | 7 | |
P304 | page(s) | 229-235 | |
P577 | publication date | 2010-02-01 | |
P1433 | published in | Journal of Thoracic Oncology | Q2448056 |
P1476 | title | A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer | |
P478 | volume | 5 |
Q84814758 | A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction |
Q35218636 | A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage |
Q47870382 | Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis. |
Q38153443 | Advances in biomarkers for esophageal cancer |
Q26825957 | Advances in targeted therapies and new promising targets in esophageal cancer |
Q58484643 | Barrett's esophagus: treatments of adenocarcinomas II |
Q38263841 | Clinical management of advanced gastric cancer: the role of new molecular drugs. |
Q38720829 | Current advances in targeted therapies for metastatic gastric cancer: improving patient care |
Q38006438 | Current developments in the management of locally advanced esophageal cancer |
Q39025928 | EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma. |
Q38110962 | Emerging tyrosine kinase inhibitors for esophageal cancer |
Q92761225 | Esophageal cancer research today and tomorrow: Lessons from algae and other perspectives |
Q49887971 | Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. |
Q37038482 | Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies |
Q37368954 | Identification of exon 19 and 21 mutations of EGFR gene in Chinese patients with esophageal squamous cell carcinoma |
Q37207101 | Impact of Treatment Modalities on Survival of Patients With Locoregional Esophageal Squamous-Cell Carcinoma in Taiwan. |
Q38221886 | Investigational therapies targeting the ErbB family in oesophagogastric cancer |
Q41907024 | Metastatic gastric cancer - focus on targeted therapies |
Q38869420 | Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology |
Q38161727 | Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. |
Q36705689 | Molecular targeted therapy for advanced gastric cancer |
Q26851986 | Outcome reporting in neoadjuvant surgical trials: a systematic review of the literature and proposals for new standards |
Q39204464 | Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer |
Q38199128 | Recent advances and future trends in the targeted therapy of metastatic gastric cancer |
Q36475391 | Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action |
Q38364292 | Targeted therapy in gastric cancer |
Q37862077 | Targeting the human EGFR family in esophagogastric cancer |
Q27853383 | The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma |
Q38222585 | The role of targeted therapy for gastrointestinal tumors. |
Q28073690 | Translational research in thoracic surgery-the National Taiwan University Hospital experience |
Search more.